Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study - Wikidata - awgldk - TriplyDB

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

http://www.wikidata.org/entity/Q28379286

about

Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.New therapeutic strategies for the treatment of male lower urinary tract symptoms Epidemiology of delayed ejaculation Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review The pathophysiology of delayed ejaculation A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction Measurement of benign prostatic hyperplasia treatment effects on male sexual function.Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.Finasteride-its impact on sexual function and prostate cancer.Annurca Apple Nutraceutical Formulation Enhances Keratin Expression in a Human Model of Skin and Promotes Hair Growth and Tropism in a Randomized Clinical Trial.Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination.

P2860

Q21089672-A151B0D9-48B8-428A-9E88-23912177B1A9 Q24564068-A34D64A3-69B1-42CB-945B-496646F93DC2 Q24795452-BB8C2C50-21FA-43AD-A2D1-6F309B4AAEAC Q26746138-27D20F19-F636-4A9A-862E-5EF5B1D05911 Q28066358-C622186E-FA2F-4FE1-975A-BB7A477516CE Q28069186-5E4B0C42-4193-4CF5-BF3B-CDFBB7AD344A Q28074466-00A6F760-6EB0-442F-AD41-A1D9D539D4C8 Q34038361-E464362B-13B2-41A5-B1C5-54F4E0C31B32 Q34209875-41AD7309-94FF-4007-BC6F-06D4897FFD46 Q34457965-A04E8E1D-43EF-464E-B608-A41933BE8403 Q34552026-9F5ABA13-80D6-4F4C-AC7F-5DF85E22F203 Q34604979-631821B0-5F5D-4B9E-90B4-2ECF6C9212D8 Q36379355-A39C1A01-1CF2-4F9E-A2DF-06D2D84EA8D2 Q37195621-6EA83C6E-032F-4A7B-85CF-5E0C7BCED425 Q37305843-7DAFEF44-7878-4B01-8942-2358F8D1C14D Q37523227-15C07CA7-7141-427B-9338-87A07D3B3233 Q37672774-0C75B561-8201-4942-9B9A-F96B059B9501 Q39681594-4AFF80E3-8C30-486D-B6EE-96573AE15E09 Q47626273-03AA238D-ECA1-4394-849F-3C167B9D27CF Q52407108-C5A6CF16-5382-42B0-B131-1661E9958060

P2860

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

http://www.wikidata.org/entity/Q28379286

description

1996 nî lūn-bûn

@nan

1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@ast

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@en

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@nl

type

label

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@ast

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@en

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@nl

prefLabel

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@ast

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@en

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@nl

P1433

Q28379286-E68E85B2-F869-4BB3-A15D-5BC909CBEFD3

P1476

Q28379286-013F6018-A600-442B-A9DF-4D633FCE3A89

P2093

Q28379286-144C1C35-5CB1-45A4-8692-A0418A15C436

Q28379286-367D0DA4-898C-480D-9BF2-86E24C2D24C1

Q28379286-52540A76-60AA-4889-9764-4A2ABCE8E95F

Q28379286-60A0C847-A4D7-4656-AFEE-6C7461C88901

Q28379286-75803A81-E3EA-4A26-9EFE-32500B2130D8

Q28379286-9AE63B15-9CF7-4604-AF02-3D7590D3E060

Q28379286-FFA9EDBF-67BD-437A-B92F-DB59B1204A47

P2860

Q28379286-06D625DF-93E0-49D7-AD5F-30FA3BC459F4

Q28379286-220875F2-E2A8-45D2-B827-4E528AB53644

Q28379286-41849706-9F51-42CA-9F0F-04010CA59BBD

Q28379286-5247FFAE-0FE4-430A-9314-AAC5E243A117

Q28379286-54503799-C89F-4B2E-86C5-1830C8A57E87

Q28379286-77697983-3339-4224-9A6C-FA856464D3D4

Q28379286-B6FC1260-1801-4069-B0A1-2E2208EACAAA

Q28379286-B90AE359-A24E-4E4A-B243-31654AE780B9

Q28379286-C4C27508-1429-48FC-8CC7-766C120C4209

Q28379286-DDCB7A20-89A4-4702-9B49-6269544E8D6D

P304

Q28379286-1BE276BB-C66D-4321-87B7-492B92AE2C85

P31

Q28379286-F38AEC8E-BCAF-40D8-B50E-554B562BF3F2

P3181

Q28379286-0AA8637B-733F-4BD3-B64C-56116A1649EF

P407

Q28379286-2295FE4B-F22E-4829-9BFA-753992FE3BD1

P433

Q28379286-9771F3C2-5CBA-493B-B600-8782F61EE1D2

P478

Q28379286-8BA1810E-A306-4228-AD20-75E9BE128887

P577

Q28379286-231B0186-1A39-45F1-99C3-A47B065C33B9

P698

Q28379286-D0B2600B-0523-4533-A798-820CB48C7A93

P932

Q28379286-1CBA0FF9-04F4-4233-A1BA-4E10DFE4E06D

P3181

P1433

Canadian Medical Association Journal

P1476

Efficacy and safety of finaste ...... ficacy Canadian Two year Study

@en

P2093

J C Nickel

http://www.w3.org/2001/XMLSchema#string

J P Perreault

http://www.w3.org/2001/XMLSchema#string

M M Elhilali

http://www.w3.org/2001/XMLSchema#string

P J Pommerville

http://www.w3.org/2001/XMLSchema#string

R C Boake

http://www.w3.org/2001/XMLSchema#string

S K Afridi

http://www.w3.org/2001/XMLSchema#string

Y Fradet

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.

Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.

Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.

A urodynamic view of prostatic obstruction and the results of prostatectomy.

Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.

The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

P304

1251-1259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2067153

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P577

1996-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8911291

http://www.w3.org/2001/XMLSchema#string

P932

1335066

http://www.w3.org/2001/XMLSchema#string